Investors

Recent Releases

March 31, 2025

Emergent BioSolutions Announces Stock Repurchase Program

GAITHERSBURG, Md. , March 31, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that its Board of Directors has authorized the repurchase of up to $50 million of the company’s common stock on or before March 27, 2026 . “As Emergent continues the turnaround phase of our

March 20, 2025

Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08

GAITHERSBURG, Md. , March 20, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a leading public health company that delivers protective and life-saving solutions to communities across the world, today announced that its Compensation Committee has granted an equity award to a newly

March 20, 2025

Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg

Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in Canada LONDON and GAITHERSBURG, Md. , March 20, 2025 (GLOBE NEWSWIRE) -- Hikma Pharmaceuticals PLC ( Hikma, Group ), the multinational generic pharmaceutical